G P Currie1, B J Lipworth2. 1. From the Consultant Chest Physician, Chest Clinic C, Aberdeen Royal Infirmary, Aberdeen, UK graeme.currie@nhs.net. 2. Consultant Chest Physician, Scottish Centre for Respiratory Research, Ninewells Hospital and Medical School, Dundee, UK.
Abstract
Since chronic obstructive pulmonary disease (COPD) is characterized by progressive airflow obstruction, inhaled bronchodilators form the mainstay of treatment. A variety of new inhaled drugs and inhaler devices have recently been licensed and approved for prescribing to patients with COPD; many such drugs have been formulated in devices to deliver two different drugs at the same time. The evidence based review article highlights all of the drugs now licensed, describes some of the evidence surrounding their use and highlights practical steps in helping decide when these drugs should be considered in the context of guidelines.
Since chronic obstructive pulmonary disease (COPD) is characterized by progressive airflow obstruction, inhaled bronchodilators form the mainstay of treatment. A variety of new inhaled drugs and inhaler devices have recently been licensed and approved for prescribing to patients with COPD; many such drugs have been formulated in devices to deliver two different drugs at the same time. The evidence based review article highlights all of the drugs now licensed, describes some of the evidence surrounding their use and highlights practical steps in helping decide when these drugs should be considered in the context of guidelines.
Authors: Andrew P Yu; Annie Guérin; Diego Ponce de Leon; Karthik Ramakrishnan; Eric Q Wu; Michelle Mocarski; Steven I Blum; Juliana Setyawan Journal: Respir Med Date: 2011-07-31 Impact factor: 3.415
Authors: Edmond L Toy; Nicolas U Beaulieu; Joshua M McHale; Timothy R Welland; Craig A Plauschinat; Andrine Swensen; Mei Sheng Duh Journal: Respir Med Date: 2010-09-29 Impact factor: 3.415
Authors: W Szafranski; A Cukier; A Ramirez; G Menga; R Sansores; S Nahabedian; S Peterson; H Olsson Journal: Eur Respir J Date: 2003-01 Impact factor: 16.671
Authors: Roland Buhl; Christian Gessner; Wolfgang Schuermann; Karin Foerster; Christian Sieder; Simone Hiltl; Stephanie Korn Journal: Thorax Date: 2015-02-12 Impact factor: 9.139
Authors: Eric D Bateman; Kenneth R Chapman; Dave Singh; Anthony D D'Urzo; Eduard Molins; Anne Leselbaum; Esther Garcia Gil Journal: Respir Res Date: 2015-08-02
Authors: J M Hohlfeld; A Sharma; J A van Noord; P J G Cornelissen; E Derom; L Towse; V Peterkin; B Disse Journal: J Clin Pharmacol Date: 2013-11-27 Impact factor: 3.126